Manzo Pharmaceuticals, Inc. (MNZO)

Manzo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2004	FY 2003	FY 2002
Period Ending	Sep 30, 2005	Dec 31, 2004	Dec 31, 2003	Dec 31, 2002
Revenue	-	3.07	3	2.03
Revenue Growth (YoY)	-	2.22%	48.23%	-
Cost of Revenue	0.52	3.05	2.25	2.75
Gross Profit	-0.52	0.02	0.76	-0.73
Selling, General & Admin	3.72	2.87	3.05	3.68
Operating Expenses	3.81	3.22	4	4.64
Operating Income	-4.33	-3.2	-3.25	-5.36
Interest Expense	-0.61	-0.91	-0.8	-0.97
Currency Exchange Gain (Loss)	-0.09	-0.03	0.09	-0.56
Other Non Operating Income (Expenses)	3.17	-	0.01	0.02
EBT Excluding Unusual Items	-1.86	-4.14	-3.95	-6.87
Gain (Loss) on Sale of Assets	9.7	-0.01	-	-
Pretax Income	7.75	-4.15	-3.95	-6.87
Net Income	7.75	-4.15	-3.95	-6.87
Net Income to Common	7.75	-4.15	-3.95	-6.87
Shares Outstanding (Basic)	4	3	3	3
Shares Outstanding (Diluted)	4	3	3	3
Shares Change (YoY)	23.26%	7.49%	15.16%	-
EPS (Basic)	1.95	-1.20	-1.23	-2.45
EPS (Diluted)	1.91	-1.20	-1.23	-2.45
Free Cash Flow	-9.71	-1.11	-1.59	-3.73
Free Cash Flow Per Share	-2.44	-0.32	-0.49	-1.33
Gross Margin	-	0.68%	25.17%	-35.80%
Operating Margin	-	-104.16%	-108.14%	-264.69%
Profit Margin	-	-135.20%	-131.63%	-339.15%
Free Cash Flow Margin	-	-36.19%	-52.82%	-184.10%
EBITDA	-4.24	-2.85	-2.3	-4.4
EBITDA Margin	-	-92.95%	-76.48%	-217.28%
D&A For EBITDA	0.08	0.34	0.95	0.96
EBIT	-4.33	-3.2	-3.25	-5.36
EBIT Margin	-	-104.16%	-108.14%	-264.69%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.